VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrants to purchase common shares partially exercised their option to purchase an additional 1,536,363 common shares at a public offering price of $1.64 per common share. Th.

VBI Vaccines Announces Closing of Underwriters' Partial Exercise of Option to Purchase Additional Common Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. It can be expected that hepatitis D will also be prevented by immunizati.

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Amyris

MannKind

Moderna

Novavax

Ocugen, Inc.

Cassava Sciences Inc

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered directing offering for shares of VBIV stock.

Why Is VBI Vaccines (VBIV) Stock Down 40% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the pricing of its previously announced underwritten public offering of 10,909,091 common shares and accompanying common warrants to purchase up to 10,909,091 common shares, and its concurrent registered direct offering of 1,818,182 common shares and accompanying common warrants.

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI in Greater China and Asia Pacific markets Company to host conference call on July 6 at 8:30 AM (HKT) / July 5 at 8:30 PM (EST) BEIJING and DURHAM, N.C., July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into license agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), expanding the companies' collaboration in the hepatitis B virus (HBV) field.

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants to purchase its common shares. VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the nu.

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences (“Brii Bio”) (Stock code: 2137.HK). Through two license and collaboration agreements, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI's HBV immunotherapeutic candidate, to global righ.

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

Vir Biotechnology

Late-breaking data from BRII-835 + PEG-IFN- a  study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment  New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vaccine PreHevbrio ® Data support the continued development of BRII-835, BRII-877 and BRII-179 to achieve best-in-class functional cure in broad HBV patient populations DURHAM, N.C. and BEIJING , June 25, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that its strategic partners, Vir Biotechnology, Inc. ("Vir," NASDAQ: VIR) and VBI Vaccines, Inc. ("VBI," NASDAQ: VBIV), presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral (HBV) infection at the European Association for the Study of the Liver (EASL) Congress 2023 that further support the clinical evaluation of Brii Bio's assets as a potential best-in-class functional cure for chronic HBV infection.

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the United Kingdom (“U.K.”) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. It can be expected that hepatitis D will also be prevented by immunizati.

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI's 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the.

VBI Vaccines Announces Poster Presentation at EASL 2023

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023. Jeff Baxter, VBI's President and CEO, commented: “As highlighted earlier this year, we continue to focus on three core priorities: (1) making a difference in the fight against hepatitis B including prevention.

VBI Vaccines Reports First Quarter 2023 Financial Results

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI's Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical comp.

VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc.

VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2022.

VBI Vaccines Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI's President and CEO, and David E. Anderson, VBI's Chief Scientific Officer, will discuss the company's hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc.

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 2 study evaluating the combination of VBI-2601 (BRII-179), VBI's HBV immunotherapeutic candidate, and BRII-835 (VIR-2218), an HBV-targeting siRNA candidate, in chronically infected HBV patients.

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

OTTAWA, Ontario & CAMBRIDGE, Mass.--( BUSINESS WIRE )--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18 years of age and older. It can be expected that hepatitis D will also be prevented by immunization with PreHevbrio as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

OSLO, Norway & CAMBRIDGE, Mass.--( BUSINESS WIRE )--The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future ‘Coronavirus X'.

CEPI Boosts ‘Coronavirus X' Vaccine Search With Expanded VBI Vaccines Deal

CAMBRIDGE, Mass.--( BUSINESS WIRE )--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.

News for VBI Vaccines Stock (VBIV)